Simetić, L., Blažičević, K., Ladenhauser, T., Golčić, M., Majnarić, T. i Herceg, D. (2021). Analysis of clinical factors associated with survival in patients with soft-tissue sarcoma receiving trabectedin. Anti-Cancer Drugs, 32., 1058-1066. doi: 10.1097/CAD.0000000000001101
Simetić, Luka, et al. "Analysis of clinical factors associated with survival in patients with soft-tissue sarcoma receiving trabectedin." Anti-Cancer Drugs, vol. 32, 2021, str. 1058-1066. https://doi.org/10.1097/CAD.0000000000001101
Simetić, Luka, Krešimir Blažičević, Tatjana Ladenhauser, Marin Golčić, Tea Majnarić i Davorin Herceg. "Analysis of clinical factors associated with survival in patients with soft-tissue sarcoma receiving trabectedin." Anti-Cancer Drugs 32 (2021): 1058-1066. https://doi.org/10.1097/CAD.0000000000001101
Simetić, L., et al. (2021) 'Analysis of clinical factors associated with survival in patients with soft-tissue sarcoma receiving trabectedin', Anti-Cancer Drugs, 32, str. 1058-1066. doi: 10.1097/CAD.0000000000001101
Simetić L, Blažičević K, Ladenhauser T, Golčić M, Majnarić T, Herceg D. Analysis of clinical factors associated with survival in patients with soft-tissue sarcoma receiving trabectedin. Anti-Cancer Drugs [Internet]. 2021. [pristupljeno 20.08.2024.];32:1058-1066. doi: 10.1097/CAD.0000000000001101
L. Simetić, K. Blažičević, T. Ladenhauser, M. Golčić, T. Majnarić i D. Herceg, "Analysis of clinical factors associated with survival in patients with soft-tissue sarcoma receiving trabectedin", Anti-Cancer Drugs, vol. 32, str. 1058-1066, 2021. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:585173. [Citirano: 20.08.2024.]